185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab. (December 2022) - Wick, W.; Gamelas Magalhaes, J.; Dos Santos Leite, A.M.; IdBaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Mildenberger, I.; Herrlinger, U.; Touat, M.; et al.